Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Influenza

  Free Subscription


12.02.2024

1 Arch Virol
1 Biochemistry
3 BMC Pediatr
4 BMJ
2 Cell
1 Epidemiol Infect
1 J Gen Virol
3 J Immunol
8 J Infect
1 J Infect Dis
2 J Virol
4 JAMA
1 Lancet
1 MMWR Morb Mortal Wkly Rep
19 PLoS One
3 Proc Natl Acad Sci U S A
15 Vaccine
1 Virology
1 Virus Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Arch Virol

  1. KIM HJ, Park JG, Moon KS, Jung SB, et al
    Identification and characterization of a marine bacterium extract from Mameliella sp. M20D2D8 with antiviral effects against influenza A and B viruses.
    Arch Virol. 2024;169:41.
    PubMed         Abstract available


    Biochemistry

  2. TOWNSEND JA, Fapohunda O, Wang Z, Pham H, et al
    Differences in Oligomerization of the SARS-CoV-2 Envelope Protein, Poliovirus VP4, and HIV Vpu.
    Biochemistry. 2024;63:241-250.
    PubMed         Abstract available


    BMC Pediatr

  3. AKHTAR S, Anis I, Kumar NA, Ihsan MT, et al
    Assessing pattern of the Pediatric Multisystem Inflammatory Syndrome (PMIS) in children during the COVID-19 pandemic: experience from the emergency department of tertiary care center of a low-middle-income country.
    BMC Pediatr. 2024;24:98.
    PubMed         Abstract available

  4. ABUSHAHIN A, Toma H, Alnaimi A, Abu-Hasan M, et al
    Impact of COVID?19 pandemic restrictions and subsequent relaxation on the prevalence of respiratory virus hospitalizations in children.
    BMC Pediatr. 2024;24:91.
    PubMed         Abstract available

  5. BAKHTIARI E, Moazzen N
    Pulmonary function in children post -SARS-CoV-2 infection: a systematic review and meta-analysis.
    BMC Pediatr. 2024;24:87.
    PubMed         Abstract available


    BMJ

  6. FELDMAN JM, Bassett MT
    US public health after covid-19: learning from the failures of the hollow state and racial capitalism.
    BMJ. 2024;384:e076969.
    PubMed        

  7. MORRISON JS, Gayle HD
    After covid-19: the case for optimism for US leadership in global health.
    BMJ. 2024;384:q138.
    PubMed        

  8. WISE J
    Covid inquiry: Tears and tensions as Sturgeon takes the stand.
    BMJ. 2024;384:q289.
    PubMed        

  9. LADDS E, Darbyshire JL, Bakerly ND, Falope Z, et al
    Cognitive dysfunction after covid-19.
    BMJ. 2024;384:e075387.
    PubMed        


    Cell

  10. QU P, Xu K, Faraone JN, Goodarzi N, et al
    Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
    Cell. 2024;187:585-595.
    PubMed         Abstract available

  11. ZHANG L, Kempf A, Nehlmeier I, Cossmann A, et al
    SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.
    Cell. 2024;187:596-608.
    PubMed         Abstract available


    Epidemiol Infect

  12. ROSNER BM, Falkenhorst G, Kumpf I, Enssle M, et al
    Case-control study of behavioural and societal risk factors for sporadic SARS-CoV-2 infections, Germany, 2020-2021 (CoViRiS study).
    Epidemiol Infect. 2024;152:e16.
    PubMed         Abstract available


    J Gen Virol

  13. HARDISTY G, Nicol MQ, Shaw DJ, Bennet ID, et al
    Latent gammaherpesvirus infection enhances type I IFN response and reduces virus spread in an influenza A virus co-infection model.
    J Gen Virol. 2024;105.
    PubMed         Abstract available


    J Immunol

  14. DHANUSHKODI NR, Prakash S, Quadiri A, Zayou L, et al
    Antiviral and Anti-Inflammatory Therapeutic Effect of RAGE-Ig Protein against Multiple SARS-CoV-2 Variants of Concern Demonstrated in K18-hACE2 Mouse and Syrian Golden Hamster Models.
    J Immunol. 2024;212:576-585.
    PubMed         Abstract available

  15. BRADSHAW CM, Georgieva T, Tankersley TN, Taylor-Doyle T, et al
    Cutting Edge: Characterization of Low Copy Number Human Angiotensin-Converting Enzyme 2-Transgenic Mice as an Improved Model of SARS-CoV-2 Infection.
    J Immunol. 2024;212:523-528.
    PubMed         Abstract available

  16. TANDON P, Abrams ND, Avula LR, Carrick DM, et al
    Unraveling Links between Chronic Inflammation and Long COVID: Workshop Report.
    J Immunol. 2024;212:505-512.
    PubMed         Abstract available


    J Infect

  17. MURRAY JM, Murray DD, Schvoerer E, Akand EH, et al
    SARS-CoV-2 Delta and Omicron community transmission networks as added value to contact tracing.
    J Infect. 2024 Jan 17:S0163-4453(24)00023-9. doi: 10.1016/j.jinf.2024.
    PubMed         Abstract available

  18. CORNISH EF, van der Meeren LE, van der Hoorn MP, Schoenmakers S, et al
    Stillbirths due to placental COVID infection associated with chronic histiocytic intervillositis do not recur in subsequent pregnancies.
    J Infect. 2024 Jan 11:S0163-4453(24)00020-3. doi: 10.1016/j.jinf.2024.
    PubMed        

  19. ZHANG H, Zhou K, Peng F, Gao Z, et al
    Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency.
    J Infect. 2024 Jan 6:S0163-4453(23)00600-X. doi: 10.1016/j.jinf.2023.
    PubMed        

  20. ZONG K, Yuan P, Wang R, Luo Q, et al
    Characteristics of innate, humoral and cellular immunity in children with non-severe SARS-CoV-2 infection.
    J Infect. 2023 Dec 13:S0163-4453(23)00589-3. doi: 10.1016/j.jinf.2023.
    PubMed         Abstract available

  21. FERNANDEZ-DE-LAS-PENAS C, Notarte KI, Macasaet R, Velasco JV, et al
    Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis.
    J Infect. 2023 Dec 13:S0163-4453(23)00590-X. doi: 10.1016/j.jinf.2023.
    PubMed         Abstract available

  22. STRAHM C, Kahlert CR, Gusewell S, Vuichard-Gysin D, et al
    Evolution of symptoms compatible with post-acute sequelae of SARS-CoV-2 (PASC) after Wild-type and/or Omicron BA.1 infection: A prospective healthcare worker cohort.
    J Infect. 2023 Dec 7:S0163-4453(23)00588-1. doi: 10.1016/j.jinf.2023.
    PubMed        

  23. GRAU S, Vela JM, Gurt A, Barcelo-Vidal J, et al
    Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients.
    J Infect. 2023 Nov 20:S0163-4453(23)00562-5. doi: 10.1016/j.jinf.2023.
    PubMed        

  24. DIEP AN, Schyns J, Gourzones C, Goffin E, et al
    How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity dynamics: an 18-month longitudinal study.
    J Infect. 2023 Nov 17:S0163-4453(23)00558-3. doi: 10.1016/j.jinf.2023.
    PubMed        


    J Infect Dis

  25. MUNOZ-QUILES C, Lopez-Lacort M, Urchueguia A, Diez-Domingo J, et al
    Risk of cardiovascular events after influenza: A population-based Self Controlled Case Series study, Spain 2011-2018.
    J Infect Dis. 2024 Feb 8:jiae070. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  26. YANG Q, Barbachano-Guerrero A, Fairchild LM, Rowland TJ, et al
    Macrophages derived from human induced pluripotent stem cells (iPSCs) serve as a high-fidelity cellular model for investigating HIV-1, dengue, and influenza viruses.
    J Virol. 2024 Feb 7:e0156323. doi: 10.1128/jvi.01563.
    PubMed         Abstract available

  27. SHINGAI M, Iida S, Kawai N, Kawahara M, et al
    Extraction of the CDRH3 sequence of the mouse antibody repertoire selected upon influenza virus infection by subtraction of the background antibody repertoire.
    J Virol. 2024 Feb 7:e0199523. doi: 10.1128/jvi.01995.
    PubMed         Abstract available


    JAMA

  28. NORMAN M, Magnus MC, Soderling J, Juliusson PB, et al
    Neonatal Outcomes After COVID-19 Vaccination in Pregnancy.
    JAMA. 2024;331:396-407.
    PubMed         Abstract available

  29. FELDSTEIN LR, Britton A, Grant L, Wiegand R, et al
    Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
    JAMA. 2024;331:408-416.
    PubMed         Abstract available

  30. RUBIN R
    As COVID-19 Cases Surge, Here's What to Know About JN.1, the Latest SARS-CoV-2 "Variant of Interest".
    JAMA. 2024 Jan 12. doi: 10.1001/jama.2023.27841.
    PubMed        

  31. RUBIN R
    From "Immunity Debt" to "Immunity Theft"-How COVID-19 Might Be Tied to Recent Respiratory Disease Surges.
    JAMA. 2024 Jan 10. doi: 10.1001/jama.2023.26608.
    PubMed        


    Lancet

  32. MCCLOSKEY B, Saito T, Shimada S, Ikenoue C, et al
    The Tokyo 2020 and Beijing 2022 Olympic Games held during the COVID-19 pandemic: planning, outcomes, and lessons learnt.
    Lancet. 2024 Jan 17:S0140-6736(23)02635-1. doi: 10.1016/S0140-6736(23)02635.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  33. LINK-GELLES R, Ciesla AA, Mak J, Miller JD, et al
    Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Pro
    MMWR Morb Mortal Wkly Rep. 2024;73:77-83.
    PubMed         Abstract available


    PLoS One

  34. WANG Y, Livingston M, McArthur DP, Bailey N, et al
    Enhancing our understanding of short-term rental activity: A daily scrape-based approach for Airbnb listings.
    PLoS One. 2024;19:e0298131.
    PubMed         Abstract available

  35. MANEEJUK P, Sukinta P, Chinkarn J, Yamaka W, et al
    Does the resumption of international tourism heighten COVID-19 transmission?
    PLoS One. 2024;19:e0295249.
    PubMed         Abstract available

  36. COZEN AE, Carton T, Hamad R, Kornak J, et al
    Factors associated with anxiety during the first two years of the COVID-19 pandemic in the United States: An analysis of the COVID-19 Citizen Science study.
    PLoS One. 2024;19:e0297922.
    PubMed         Abstract available

  37. MALM KL, Peprah NY, Mohammed W, Adomako BY, et al
    A retrospective analysis of malaria deaths in the pre- and intra- COVID 19 pandemic era, Ghana, 2016-2021.
    PLoS One. 2024;19:e0286212.
    PubMed         Abstract available

  38. GARENNE M, Stiegler N
    Covid-19 demography in France and South Africa: A comparative study of morbidity and mortality in 2020-2022.
    PLoS One. 2024;19:e0294870.
    PubMed         Abstract available

  39. MENNIS E, Hobus M, van den Muijsenbergh M, van Loenen T, et al
    COVID-19 related morbidity and mortality in people experiencing homelessness in the Netherlands.
    PLoS One. 2024;19:e0296754.
    PubMed         Abstract available

  40. CAMPOS RP, Messias Oliveira JG, de Oliveira Farias I, de Souza VCV, et al
    Effects of pulmonary rehabilitation on ventilation dynamics measured during exertion in patients with post-acute COVID-19 syndrome: A cross-sectional observational study.
    PLoS One. 2024;19:e0296707.
    PubMed         Abstract available

  41. LIU CC, Ling J, Zahry NR, Liu C, et al
    Using the Theory of Planned Behavior to determine COVID-19 vaccination intentions and behavior among international and domestic college students in the United States.
    PLoS One. 2024;19:e0293130.
    PubMed         Abstract available

  42. RICHARDSON L, Long E, Goodfellow C, Milicev J, et al
    Starting an undergraduate degree amid the COVID-19 pandemic: A mixed-method egocentric network study on student loneliness.
    PLoS One. 2024;19:e0297953.
    PubMed         Abstract available

  43. FEIFEI F
    Analyzing metaphor patterns in COVID-19 news pictures: A critical study in China.
    PLoS One. 2024;19:e0297336.
    PubMed         Abstract available

  44. STONE H, Bailey E, Wurie H, Leather AJM, et al
    A qualitative study examining the health system's response to COVID-19 in Sierra Leone.
    PLoS One. 2024;19:e0294391.
    PubMed         Abstract available

  45. YANG Y, Liu B, Wen YJ, Li ZJ, et al
    Fever clinic construction and management targeted to prevention and control of healthcare-associated respiratory viral infections in Jiangsu, China: A cross-sectional observational study.
    PLoS One. 2024;19:e0297133.
    PubMed         Abstract available

  46. DUO H, Jin M, Yang Y, Baheti R, et al
    Effect of antiplatelet therapy after COVID-19 diagnosis: A systematic review with meta-analysis and trial sequential analysis.
    PLoS One. 2024;19:e0297628.
    PubMed         Abstract available

  47. WANG Q, Gu H, Ren J, Zhao Y, et al
    Analysis of characteristics of and risk factors for otological symptoms after COVID-19 infection.
    PLoS One. 2024;19:e0297100.
    PubMed         Abstract available

  48. MCQUILLAN K, Yoshida-Montezuma Y, Jambon M, Vanderloo LM, et al
    Physical activity and unexpected weight change in Ontario children and youth during the COVID-19 pandemic: A cross-sectional analysis of the Ontario Parent Survey 2.
    PLoS One. 2024;19:e0292934.
    PubMed         Abstract available

  49. UDOAKANG AJ, Nganyewo NN, Djomkam Zune AL, Olwal CO, et al
    Knowledge, attitude and perception towards COVID-19 among representative educated sub-Saharan Africans: A cross-sectional study during the exponential phase of the pandemic.
    PLoS One. 2024;19:e0281342.
    PubMed         Abstract available

  50. GAO ZH, Li J
    Intolerance of uncertainty and mental health in China "Post-pandemic" age: The mediating role of difficulties in emotion regulation.
    PLoS One. 2024;19:e0298044.
    PubMed         Abstract available

  51. GHADER N, AlMheiri N, Fikri A, AbdulRazzak H, et al
    Prevalence and factors associated with mental illness symptoms among school students post lockdown of the COVID-19 pandemic in the United Arab Emirates: A cross-sectional national study.
    PLoS One. 2024;19:e0296479.
    PubMed         Abstract available

  52. RIBEIRO M, Azevedo L, Santos AP, Pinto Leite P, et al
    Understanding spatiotemporal patterns of COVID-19 incidence in Portugal: A functional data analysis from August 2020 to March 2022.
    PLoS One. 2024;19:e0297772.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  53. ZHAO G, Xue L, Geisler HC, Xu J, et al
    Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery.
    Proc Natl Acad Sci U S A. 2024;121:e2314747121.
    PubMed         Abstract available

  54. ZHANG Y, Bharathi V, Dokoshi T, de Anda J, et al
    Viral afterlife: SARS-CoV-2 as a reservoir of immunomimetic peptides that reassemble into proinflammatory supramolecular complexes.
    Proc Natl Acad Sci U S A. 2024;121:e2300644120.
    PubMed         Abstract available

  55. PAGLINO E, Lundberg DJ, Wrigley-Field E, Zhou Z, et al
    Excess natural-cause mortality in US counties and its association with reported COVID-19 deaths.
    Proc Natl Acad Sci U S A. 2024;121:e2313661121.
    PubMed         Abstract available


    Vaccine

  56. STELETOU E, Giannouchos T, Dimitriou G, Karatza A, et al
    Parental concerns and vaccine hesitancy against COVID-19 vaccination for children in Greece: A cross-sectional survey.
    Vaccine. 2024 Jan 6:S0264-410X(24)00003-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  57. FILIPAS DK, Labban M, Beatrici E, Stone BV, et al
    Exploring preventive care practices among unvaccinated individuals in the United States during the COVID-19 pandemic.
    Vaccine. 2024;42:441-447.
    PubMed         Abstract available

  58. KRANZLER EC, Ihongbe TO, Marshall MC, Denison B, et al
    Racial and ethnic differences in COVID-19 vaccine readiness among adults in the United States, January 2021-April 2023.
    Vaccine. 2024 Jan 4:S0264-410X(23)01537-2. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  59. BUHL C, Jacobsen R, Almarsdottir AB, Abtahi S, et al
    Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - A cross-sectional study in six EU member states.
    Vaccine. 2024 Jan 4:S0264-410X(23)01511-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  60. CHARPIGNON ML, Gupta S, Shahnaz Majumder M
    Massachusetts companion program bolsters COVID-19 vaccine rates among seniors.
    Vaccine. 2024 Jan 3:S0264-410X(23)01494-9. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  61. DAVIDSON AM, Burns S, White LA, Perlman M, et al
    "I shall not poison my child with your human experiment": Investigating predictors of parents' hesitancy about vaccinating younger children (<12) in Canada.
    Vaccine. 2024 Jan 2:S0264-410X(23)01519-0. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  62. AGASSE E, Rodriguez GF, Vilarino V, Galli JH, et al
    Social determinants of health and vaccine uptake in pregnancy: Disparities in a diverse, predominately foreign-born population.
    Vaccine. 2024 Jan 2:S0264-410X(23)01515-3. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  63. RUBIO-CASILLAS A, Rodriguez-Quintero CM, Redwan EM, Gupta MN, et al
    Do vaccines increase or decrease susceptibility to diseases other than those they protect against?
    Vaccine. 2023 Dec 28:S0264-410X(23)01506-2. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  64. SHENTON P, Schrader S, Smith J, Alafaci A, et al
    Long term follow up and outcomes of Covid-19 vaccine associated myocarditis in Victoria, Australia: A clinical surveillance study.
    Vaccine. 2023 Dec 27:S0264-410X(23)01516-5. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  65. NGUYEN KH, Coy KC, Black CL, Scanlon P, et al
    Comparison of adult hesitancy towards COVID-19 vaccines and vaccines in general in the USA.
    Vaccine. 2023 Dec 23:S0264-410X(23)01488-3. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  66. KACHKO A, Selvaraj P, Liu S, Kim J, et al
    Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models.
    Vaccine. 2023 Dec 22:S0264-410X(23)01498-6. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  67. LO E, Brousseau N, Defay F, Fortin E, et al
    Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in Quebec, Canada, during the Delta and early Omicron periods.
    Vaccine. 2023 Dec 22:S0264-410X(23)01489-5. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  68. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
    Vaccine. 2023 Dec 20:S0264-410X(23)01482-2. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  69. WOLFF M, Charpentier P, Canals A, Vial C, et al
    Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Vaccine. 2023 Dec 19:S0264-410X(23)01481-0. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available

  70. ARASHIRO T, Miwa M, Nakagawa H, Takamatsu J, et al
    COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study).
    Vaccine. 2023 Dec 18:S0264-410X(23)01480-9. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available


    Virology

  71. YANG J, Lan R, Chang H, Li H, et al
    Isolation and characterization of genotype 4 Eurasian avian-like H1N1 influenza virus in pigs suffering from pneumonia.
    Virology. 2024;592:110009.
    PubMed         Abstract available


    Virus Res

  72. LI ZA, Bajpai AK, Wang R, Liu Y, et al
    Systems Genetics of Influenza A Virus-infected Mice Identifies TRIM21 as a Critical Regulator of Pulmonary Innate Immune Response.
    Virus Res. 2024 Feb 6:199335. doi: 10.1016/j.virusres.2024.199335.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.